BEVERLY HILLS, CA / ACCESSWIRE / February 13, 2018 / Stony Hill Corp. (OTC:STNY) (the "Company"), a diversified company focused on the legal cannabis industry, today announces the official launch of TherPet™, an advanced full-spectrum hemp-derived CBD-based product line for pets.
According to the American Pet Products Association, Americans spent an estimated $69.4 billion on their pets in 2017, which was up from $66.8 billion in 2016. Americans have steadily spent more on their pets since 1994, the year that the American Pet Products Association began tracking and publishing this data.
The Company believes that CBD for pets will become a growing part of the animal health industry as consumers spend more and more on the quality and longevity of their pets' lives.
"Hemp-derived CBD products are seeing a growing demand in the animal health industry around the world," noted JJ Southard, Vice President of Products at Stony Hill Corp. "Ongoing research at Colorado State University and the University of Pennsylvania School of Veterinary Medicine regarding CBD for osteoarthritis, epilepsy, and more shows the tremendous potential for CBD in the animal health space," Southard continued, "We're happy to be getting into the rapidly growing industry at the ground level."
Initially, all products will be sold through TherPet's online e-commerce platform - https://therpet.com/. In the future, the Company intends to seek out retail and international distribution agreements for TherPet's products.
TherPet's initial product line includes tinctures in a range of dosages and flavors. From chicken to peanut butter - dogs, cats, and furry friends of all kinds are sure to be satisfied. In the future, the Company intends to expand the TherPet product line to include chews, treats, accessories, and more. All TherPet products have been formulated with every pet's health in mind.
About Stony Hill Corp.
Stony Hill Corp. (www.stonyhillcorp.com), is a diversified company focused on multiple areas of the cannabis, hemp and CBD industry. The company is focused on select investment, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.
Stony Hill has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.
Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend," and similar expressions, as they relate to Stony Hill Corp. (the "Company") or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company's ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Disclaimer: The U.S. Food and Drug Administration has not evaluated or endorsed these statements and strictly prohibits us from making any claims related to diseases or medical conditions in conjunction with our products.